Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
P/B ratio for Armata Pharmaceuticals, Inc. (ARMP)
P/B ratio as of 2023: -3.65
According to Armata Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -3.65. At the end of 2022 the company had a P/B ratio of 1.18.
P/B ratio history for Armata Pharmaceuticals, Inc. from 1993 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -3.65 |
| 2022 | 1.18 |
| 2021 | 5.20 |
| 2020 | 2.60 |
| 2019 | 1.74 |
| 2018 | 0.46 |
| 2017 | 0.83 |
| 2016 | 0.45 |
| 2015 | 1.69 |
| 2014 | 11.17 |
| 2013 | -3.56 |
| 2012 | 0.65 |
| 2008 | -1.16 |
| 2007 | 1.56 |
| 2006 | 9.79 |
| 2005 | 1.37 |
| 2004 | 2.47 |
| 2003 | 52.64 |
| 2002 | 43.47 |
| 2001 | 44.56 |
| 2000 | 55.72 |
| 1999 | 253.34 |
| 1998 | 40.78 |
| 1997 | 132.53 |
| 1996 | 53.00 |
| 1995 | 57.15 |
| 1994 | 33.41 |
| 1993 | 1224.71 |